TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

121 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-28

Study Completion Date

2023-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a prospective, multinational (Italy, Ireland and UK), multicenter, randomised Clinical Trial that compares the efficacy and performance of two drug coated balloon (DCB), the MAGIC TOUCH sirolimus coated balloon (Concept Medical) and SeQuent Please paclitaxel coated balloon (B Braun). The objective of the study is to compare angiographic outcomes of Magic TouchTM sirolimus coated balloon (Concept Medical) versus SeQuentTM paclitaxel coated balloon (Bbraun) for the treatment of de novo coronary artery lesions in small vessels (≤2.75 mm) with respect to Net Gain (mm) at 6 months follow-up

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions

NCT02400632

Coronary Artery Disease

COMPLETED PHASE3

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

NCT06271590

Coronary Artery Disease Native Coronary Artery Stenosis Cardiovascular Diseases

RECRUITING NA

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

NCT05908331

In-Stent Restenosis Cardiovascular Diseases Coronary Artery Disease

RECRUITING NA

Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels

NCT04893291

Coronary Artery Disease Coronary Artery Stenosis

ACTIVE_NOT_RECRUITING NA

AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease

NCT05471245

Coronary Restenosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective, randomized, multi-centre study in subjects with small vessels, i.e. at least one de-novo lesion in a small vessel (≤2.75mm). Vessel size will be determined first by QCA on-line (screening, pre-procedure). If, based on QCA on-line the vessel size pre-procedure is ≤2.75mm and following a successful pre-dilatation (i.e. no angiographic dissections type CDEF and TIMI\>2), the subject will be randomized in a 1:1 fashion to Magic Touch or SeQuent Please Neo. OCT will be performed post pre-dilatation (guidance) prior to drug coated balloon (DCB) treatment. The DCB balloon size will be selected based on OCT measurements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease DCB

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sirolimus drug coated balloon (SCB)

Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB)

Group Type EXPERIMENTAL

sirolimus drug coated balloon (SCB)

Intervention Type DEVICE

Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology "Nanolute". It is indicated (CE approved) for ISR, small vessels, bifurcation lesions \& de novo lesions.

paclitaxel releasing coronary balloon catheter.

SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter

Group Type ACTIVE_COMPARATOR

paclitaxel releasing coronary balloon catheter

Intervention Type DEVICE

SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sirolimus drug coated balloon (SCB)

Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology "Nanolute". It is indicated (CE approved) for ISR, small vessels, bifurcation lesions \& de novo lesions.

Intervention Type DEVICE

paclitaxel releasing coronary balloon catheter

SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients ≥18 years
2. Patient with chronic stable angina or stabilized acute coronary syndromes with normal cardiac biomarker values

Note: For patients showing elevated Troponin (e.g. non-STEMI patients) at baseline (within 72h pre-PCI) an additional blood sample must be collected prior to randomization to confirm that:
* hs-cTn or Troponin I or T levels are stable, i.e. the value should be within 20% range of the value found in the first sample at baseline, or have dropped
* CK-MB and CK levels are within normal range If hs-cTn or Troponin I or T levels are stable or have dropped, the CK-MB and CK levels are within normal ranges, and the ECG is normal, the patient may be included in the study.
3. The patient has a planned intervention in one or two separate major epicardial territories (LAD, LCX or RCA) and has at least one de-novo lesion in a small vessel (≤2.75mm by QCA prior to pre-dilatation)
4. Target lesion length ≤30 mm
5. Able to understand and provide informed consent and comply with all study procedures including 6 months angiographic follow-up
6. Patient must have completed the follow-up phase of any previous study

Exclusion Criteria

1. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)
2. Evidence of ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac biomarkers (according to local standard hospital practice) have not returned within normal limits at the time of procedure
3. Known contraindication or hypersensitivity to sirolimus, paclitaxel, or to medications such as aspirin, heparin, and all of the following four medications: clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor
4. Patient suffered from stroke/TIA during the last 6 months
5. LVEF \<30%
6. Platelet count \<100,000 cells/mm3 or \>400,000 cells/mm3, a WBC of \<3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis)
7. Known renal insufficiency (e.g. serum creatinine \>2.5mg/dL, or creatinine clearance ≤30 mL/min), or subject on dialysis, or acute kidney failure (as per physician judgment)
8. Patient undergoing planned surgery within 6 months with the necessity to stop DAPT
9. History of bleeding diathesis or coagulopathy
10. The patient is a recipient of a heart transplant
11. Concurrent medical condition with a life expectancy of less than 12 months
12. The patient is unwilling/not able to return for angiographic recatherisation at 6 month follow-up
13. Currently participating in another trial and not yet at its primary endpoint.

14. The patient has a planned intervention in three separate major epicardial territories (3 vessel disease)
15. The patient has a planned intervention in the left-main plus two separate major epicardial territories (left-main plus 2 vessel disease)
16. Target vessel size \>2.75 mm (by QCA)
17. Target vessel size \<2.00 mm (by QCA)
18. Target lesion has a total occlusion or TIMI flow \<2
19. Target lesion in left main stem
20. The target vessel contains visible thrombus
21. Aorto-ostial target lesion (within 3 mm of the aorta junction)
22. Moderate-severe tortuous, calcified or angulated coronary anatomy of the target vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter
23. Lesion is located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No